Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 9/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14929987 | 1.00 | USP30 (0.38) | USP30PRMT5WDR77BACE1BACE2 | |
| SCHEMBL19414609 | 0.89 | USP30 (0.37) | USP30PRMT5WDR77BACE1BACE2 | |
| SCHEMBL19414601 | 0.89 | USP30 (0.37) | USP30PRMT5WDR77BACE1BACE2 | |
| SCHEMBL17948104 | 0.89 | USP30 (0.38) | USP30PRMT5WDR77BACE1BACE2 | |
| SCHEMBL20484314 | 0.89 | USP30 (0.38) | USP30PRMT5WDR77BACE1BACE2 | |
| SCHEMBL17947975 | 0.89 | USP30 (0.38) | USP30PRMT5WDR77BACE1BACE2 | |
| SCHEMBL1293339 | 0.89 | USP30 (0.38) | USP30PRMT5WDR77BACE1BACE2 | |
| SCHEMBL1293338 | 0.89 | USP30 (0.38) | USP30PRMT5WDR77BACE1BACE2 | |
| SCHEMBL19414547 | 0.89 | USP30 (0.38) | USP30PRMT5WDR77BACE1BACE2 | |
| SCHEMBL16948373 | 0.88 | USP30 (0.40) | USP30PRMT5WDR77BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | HAVCR2, LIPC, PYGL | USP30 2386/4885PRMT5 2358/4885WDR77 3764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.